|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1650 Diagonal Road |
Address2 |
|
City | ALEXANDRIA |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1386-12
|
||||||||
|
6. House ID# 321810000
|
TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: John Aguilar |
Date | 4/22/2024 2:32:06 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
1/2/24 AAO-HNS letter to CMS on the agency's proposed rule on federal independent dispute resolution operations of the No Surprises Act.
1/8/24 Coalition letter to Administrator of the Centers for Medicare and Medicaid Services (CMS); includes issues relating to classification/coverage of prescription drugs and exchange network adequacy standards.
1/9/24 AAO-HNS led letter to House Energy & Commerce and Ways & Means Committees opposing the Medicare Audiology Access Improvement Act (H.R. 6445)
1/24/24 Coalition letter to leadership of the Senate HELP Committee opposing Section 5 of the "Health Care PRICE Transparency Act 2.0." Suggests pursuing alternative course of action to better support ASCs.
2/15/24 Coalition letter thanking members for reauthorizing the "Dr. Lorna Breen Health Care Provider Protection Act." Encourages members to continue supporting mental health services for healthcare professionals.
2/16/24 Letter to FDA; issues relating to public comment and FDA best practices.
3/1/24 Coalition letter to Director of the Center for Medicare at the Centers for Medicare and Medicaid Services (CMS); includes issues relating to network adequacy, the Star Ratings system, and prior authorization.
3/15/24 Letter to Chair and Ranking Member of House Committee on Education and the Workforce; Issues relating to prior authorization reform and administrative burden; including ERISA and H.R. 2630 (The Safe Step Act).
3/18/24 Letter to Reps. Michael Burgess and Diana DeGette offering the AAO-HNS' support of H.R. 766 (Dr. Michael C. Burgess Preventive Health Savings Act) and reform of the CBO scoring system.
Issues related to hearing healthcare, in general.
Issues pertaining to health information technology and electronic health records, in general.
Issues pertaining to Graduate Medical Education, in general.
Issues pertaining to healthcare liability reform, in general.
Issues pertaining to prior authorization, in general
Issues pertaining to Medicare physician reimbursement, related to the Strengthening Medicare for Patients and Providers Act (H.R. 2474) and the Preserving Seniors Access to Physicians Act of 2023 (H.R. 6683), and in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
1/2/24 AAO-HNS letter to CMS on the agency's proposed rule on federal independent dispute resolution operations of the No Surprises Act.
1/8/24 Coalition letter to Administrator of the Centers for Medicare and Medicaid Services (CMS); includes issues relating to classification/coverage of prescription drugs and exchange network adequacy standards.
1/17/24 Coalition letter urging House and Senate leadership to reverse the 3.37% cut to Medicare physician payments that took effect on January 1st, 2024.
3/1/24 Coalition letter to Director of Medicare at the Centers for Medicare and Medicaid Services (CMS); includes issues relating to network adequacy, the Star Ratings system, and prior authorization.
Issues pertaining to prior authorization, in general
Issues pertaining to Medicare physician reimbursement, related to the Strengthening Medicare for Patients and Providers Act (H.R. 2474) and the Preserving Seniors Access to Physicians Act of 2023 (H.R. 6683), and in general.
Issues related to hearing healthcare, in general.
Issues pertaining to step therapy, in general.
Issues pertaining to health information technology and electronic health records, in general.
Issues pertaining to Graduate Medical Education, in general.
Issues pertaining to healthcare liability reform, in general
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Medicare Payment Advisory Commission (MedPAC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
1/9/24 Coalition to letter to Chairs and Ranking Members of the House and Senate Committees on Appropriations urging that appropriations for FY 2024 retain the FDA's authority to regulate tobacco products and do not cut funding from the CDC's Office on Smoking and Health (OSH).
3/25/24 Coalition letter to the Chair and Ranking Member of the Senate Subcommittee on Labor, Health and Human Services, Education and Related Agencies to fund the CDC's Office on Smoking and Health (OSH) at $310 million for FY 2025.
3/25/24 Coalition letter to the Chair and Ranking Member of the House Subcommittee on Labor, Health and Human Services, Education and Related Agencies to fund the CDC's Office on Smoking and Health (OSH) at $310 million for FY 2025.
Issues pertaining to tobacco control, including the pending FDA rule on prohibiting menthol cigarettes, and in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
1/9/24 Coalition to letter to Chairs and Ranking Members of the House and Senate Committees on Appropriations urging that appropriations for FY 2024 retain the FDA's authority to regulate tobacco products and do not cut funding from the CDC's Office on Smoking and Health (OSH).
1/17/24 Coalition letter urging House and Senate leadership to reverse the 3.37% cut to Medicare physician payments that took effect on January 1st, 2024.
3/18/24 Letter to Reps. Michael Burgess and Diana DeGette offering the AAO-HNS' support of H.R. 766 (Dr. C Burgess Preventive Health Savings Act) and reform of the CBO scoring system.
3/25/24 Coalition letter to the Chair and Ranking Member of the Senate Subcommittee on Labor, Health and Human Services, Education and Related Agencies to fund the CDC's Office on Smoking and Health (OSH) at $310 million for FY 2025.
3/25/24 Coalition letter to the Chair and Ranking Member of the House Subcommittee on Labor, Health and Human Services, Education and Related Agencies to fund the CDC's Office on Smoking and Health (OSH) at $310 million for FY 2025.
Issues pertaining to the budget and appropriations, in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Issues pertaining to healthcare practice and the Federal Supremacy Clause at the Department of Veterans Affairs, in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |